IRT and CMT β-lactamases and inhibitor resistance

被引:85
作者
Canton, R. [1 ]
Morosini, M. I. [1 ]
Martin, O. [1 ]
de la Maza, S. [1 ]
de la Pedrosa, E. Gomez G. [1 ]
机构
[1] Hosp Univ Ramon & Cajal, Microbiol Serv, Madrid 28034, Spain
关键词
class A beta-lactamase inhibitors; clavulanate; inhibitor-resistant beta-lactamases; IRT; review;
D O I
10.1111/j.1469-0691.2007.01849.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Acquired resistance to penicillin-beta-lactamase inhibitor combinations in Escherichia coli is due to: (i) penicillinase hyperproduction due to the presence of the bla(TEM-1) gene in small multicopy plasmids or strong promoters; (ii) overproduction of constitutive AmpC cephalosporinase; and (iii) OXA-type and inhibitor-resistant TEM (IRT) beta-lactamases. IRT enzymes emerge via mutational events from TEM-1 or TEM-2 beta-lactamases that affect substrate affinity for v-lactamase inhibitors. They are mainly isolated in urinary infections from community patients. Prevalence is variable, depending on geographical area, detection methods and potential selection pressure. These enzymes may evolve into complex mutants (CMT enzymes), which also confer resistance to extended-spectrum cephalosporins. CTX-M enzymes with the IRT phenotype have not been detected to date. New studies of IRT enzymes, including population structure, association with virulence traits and plasmid dispersion, are needed.
引用
收藏
页码:53 / 62
页数:10
相关论文
共 67 条
[41]   Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different β-lactam resistance phenotypes [J].
Oliver, A ;
Pérez-Vázquez, M ;
Martínez-Ferrer, M ;
Baquero, F ;
De Rafael, L ;
Cantón, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :862-867
[42]  
Page MI, 1999, CURR PHARM DESIGN, V5, P895
[43]   COMPARATIVE ACTIVITIES OF CLAVULANIC ACID, SULBACTAM, AND TAZOBACTAM AGAINST CLINICALLY IMPORTANT BETA-LACTAMASES [J].
PAYNE, DJ ;
CRAMP, R ;
WINSTANLEY, DJ ;
KNOWLES, DJC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :767-772
[44]   Mechanisms of reduced susceptibility to amoxycillin-clavulanic acid in Escherichia coli strains from the health region of Tortosa (Catalonia, Spain) [J].
Pérez-Moreno, MO ;
Pérez-Moreno, M ;
Carulla, M ;
Rubio, C ;
Jardí, AM ;
Zaragoza, J .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (03) :234-241
[45]   EXTENDED-SPECTRUM BETA-LACTAMASES [J].
PHILIPPON, A ;
LABIA, R ;
JACOBY, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1131-1136
[46]   TEM-121, a novel complex mutant of TEM-type β-lactamase from Enterobacter aerogenes [J].
Poirel, L ;
Mammeri, H ;
Nordmann, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4528-4531
[47]   Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant [J].
Prinarakis, EE ;
Miriagou, V ;
Tzelepi, E ;
Gazouli, M ;
Tzouvelekis, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) :838-840
[48]   Amino acid substitutions causing inhibitor resistance in TEM β-lactamases compromise the extended-spectrum phenotype in SHV extended-spectrum β-lactamases [J].
Randegger, CC ;
Hächler, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (05) :547-554
[49]   FACTORS DETERMINING RESISTANCE TO BETA-LACTAM COMBINED WITH BETA-LACTAMASE INHIBITORS IN ESCHERICHIA-COLI [J].
REGUERA, JA ;
BAQUERO, F ;
PEREZDIAZ, JC ;
MARTINEZ, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 (05) :569-575
[50]   TEM-109 (CMT-5), a natural complex mutant of TEM-1 β-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5) [J].
Robin, F ;
Delmas, J ;
Chanal, C ;
Sirot, D ;
Sirot, J ;
Bonnet, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4443-4447